When using GLP-1 drugs, people experience a physiological change that results in eating smaller meals, consuming fewer calories, and eating less often, while also altering their mental reward system which replaces food and snacking with some other treat
Providers typically reduce insulin or sulfonylurea doses when initiating semaglutide
Simultaneously, the production of ketone bodies during fat metabolism can compete with uric acid for renal excretion, reducing the kidneys' ability to eliminate uric acid efficiently
The dose range typically goes from 2.5 mg to 15 mg once a week, depending on a persons needs and how well they tolerate the medicine
Additionally, while each agent is individually safe, clinical data on concurrent use remains limited
& Owsianik, G